Jardiance Cost in Pennsylvania 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Jardiance Actually Cost in Pennsylvania Right Now?

Brand-name Jardiance has a manufacturer list price of approximately $680 per month for a 30-tablet supply in Pennsylvania, regardless of dose (10 mg or 25 mg). Most commercially insured patients pay far less after insurance adjustments and copay assistance. Cash-pay patients without any assistance face the full retail price, which has held near this figure since the drug's label expansion to heart failure and chronic kidney disease.

Empagliflozin is an SGLT2 inhibitor approved by the FDA for type 2 diabetes (T2D), heart failure with reduced and preserved ejection fraction, and chronic kidney disease (CKD) [1]. The 10 mg dose is the standard starting point for T2D; the 25 mg dose is used when additional glycemic control is needed. Once-daily oral dosing applies to both indications.

Prices across Pennsylvania retail chains such as CVS, Rite Aid (where operating), Walgreens, and Giant Food Stores track closely to the list price without a discount program. GoodRx and similar discount platforms have offered negotiated prices in the $600, $660 range at select Pennsylvania locations, though those figures shift monthly.

The EMPA-REG OUTCOME trial (N=7,020) published in the New England Journal of Medicine in 2015 established that empagliflozin 10 mg or 25 mg reduced the rate of the composite cardiovascular outcome by 14% vs. placebo (hazard ratio 0.86 to 95% CI 0.74, 0.99, P<0.001 for superiority), and cut cardiovascular death by 38% [2]. That evidence is the primary driver of insurer and Medicaid formulary inclusion in Pennsylvania.

The EMPEROR-Reduced trial (N=3,730) confirmed a 25% reduction in the composite of cardiovascular death or hospitalization for heart failure vs. placebo (HR 0.75 to 95% CI 0.65, 0.86, P<0.001) [3]. EMPEROR-Preserved (N=5,988) extended the heart failure benefit to patients with ejection fraction above 40% [4].

For CKD, the EMPA-KIDNEY trial (N=6,609) showed empagliflozin 10 mg reduced the risk of kidney disease progression or cardiovascular death by 28% vs. placebo (HR 0.72 to 95% CI 0.64, 0.82, P<0.001) [5]. These trial results collectively explain why Pennsylvania Medicaid, Medicare Part D plans, and commercial insurers treat empagliflozin as a preferred agent rather than a specialty-tier afterthought.

Pennsylvania Medicaid Coverage for Empagliflozin

Pennsylvania Medicaid (Medical Assistance) covers Jardiance for T2D, heart failure, and CKD, but prior authorization (PA) is required in most managed care organization (MCO) contracts. The request form must document the qualifying diagnosis, HbA1c or echocardiographic data, and a record of at least one earlier trial of metformin for T2D indications.

Pennsylvania runs its Medicaid program largely through five MCOs: AmeriHealth Caritas PA, Geisinger Health Plan, Highmark Wholecare, UPMC for You, and UnitedHealthcare Community Plan. Each MCO maintains its own preferred drug list (PDL). As of 2025, most PA MCO PDLs place empagliflozin on a preferred specialty or preferred brand tier with prior authorization rather than non-formulary status, which means coverage is achievable rather than exceptional [6].

The 2023 American Diabetes Association Standards of Care specify that "in patients with type 2 diabetes and established CVD or high cardiovascular risk, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended" [7]. Pennsylvania Medicaid clinical reviewers align with ADA guidance, making a PA approval more straightforward when documentation is organized.

Medicaid-enrolled Pennsylvania patients approved through prior authorization typically pay $0, $3.50 per fill under the state copay structure. Fee-for-service Medical Assistance (for patients not enrolled in an MCO) uses the Pennsylvania Department of Human Services PDL, which also lists empagliflozin as covered with prior authorization.

Children enrolled in CHIP (Children's Health Insurance Program) in Pennsylvania are unlikely to need empagliflozin given the drug's adult indication profile, but adolescents with monogenic diabetes or rare circumstances may qualify under case-by-case review.

Which Pennsylvania Commercial Insurance Plans Cover Jardiance?

Most large commercial plans operating in Pennsylvania, including Independence Blue Cross, Highmark Blue Cross Blue Shield, Aetna, Cigna, and UnitedHealthcare, place Jardiance on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) of their formularies. Tier placement is the single biggest variable in what a patient pays out of pocket.

Tier 3 copays in Pennsylvania commercial plans typically run $50, $100 per 30-day fill before meeting the deductible, and $30, $60 after. Tier 4 placement often means 20 to 30% coinsurance rather than a flat copay, which at a $680 list price translates to $136, $204 per fill even after the deductible is met.

The AHA/ACC 2022 Heart Failure Guidelines give empagliflozin a Class I, Level of Evidence A recommendation for patients with HFrEF [8]. Insurers frequently use that guideline classification to justify formulary inclusion over step-therapy requirements, meaning patients with a documented HF diagnosis may bypass metformin or other step-therapy requirements that apply to the T2D indication.

Pennsylvania's Act 146 of 2019 limits step-therapy overrides to 30 days for most plans regulated by the Pennsylvania Insurance Department, though self-insured ERISA plans are not subject to state override timelines. Patients on ERISA plans experiencing step-therapy barriers should work with their prescriber to submit a peer-to-peer review request.

Medicare Part D enrollees in Pennsylvania should check their specific plan's formulary each October during open enrollment. The Medicare Prescription Drug Coverage and Patient Access Act changes phased in for 2025 to 2026 cap out-of-pocket drug costs at $2,000 annually for Part D enrollees, which meaningfully reduces the annual burden for Jardiance users who previously faced thousands in coinsurance [9].

How the Boehringer Ingelheim / Lilly Savings Card Works in Pennsylvania

Boehringer Ingelheim and Eli Lilly co-promote Jardiance and jointly operate a patient savings program. Commercially insured Pennsylvania patients who are not enrolled in any federal or state government health program (Medicaid, Medicare, TRICARE, or similar) may use the Jardiance savings card to pay as little as $10 per 30-day or 90-day prescription fill.

The savings card functions as secondary coverage. The pharmacist processes the commercial insurance claim first, then applies the savings card to the remaining copay or coinsurance up to the program's monthly cap. The cap as of 2025 has been $150 per fill for most eligible patients, meaning patients with coinsurance above that amount may still owe a balance.

Enrollment is online at the Jardiance website or via the prescribing provider's office. The card cannot be used in combination with any government insurance at the point of sale. Pennsylvania patients on Medicare Part D, for instance, are ineligible for the savings card but may qualify for Boehringer Ingelheim's separate patient assistance program (PAP), which provides free medication for patients below 400% of the federal poverty level.

Boehringer Ingelheim's PAP for Jardiance has no Pennsylvania-specific restriction. Applications require proof of income, a current prescription, and confirmation that the patient lacks adequate prescription coverage. Processing typically takes two to four weeks for the first shipment.

Compounded Empagliflozin in Pennsylvania: Legal Status and Cost

Compounded empagliflozin is legal in Pennsylvania when prepared by a licensed 503A compounding pharmacy operating under state board of pharmacy oversight and federal USP standards. The 503A designation refers to traditional compounding pharmacies that fill patient-specific prescriptions, as distinct from 503B outsourcing facilities that produce large-batch products for healthcare institutions [10].

Empagliflozin is not on the FDA's list of bulk drug substances approved for compounding under 503A as of mid-2025 [10]. This regulatory detail matters: 503A pharmacies may compound using commercially available finished drug products as the starting material in some circumstances, but compounding from bulk API (active pharmaceutical ingredient) requires that the API appear on the FDA's 503A bulk substances list. Pennsylvania prescribers and patients should confirm with the specific compounding pharmacy exactly how the preparation is sourced and whether it complies with current FDA guidance before proceeding.

The cost advantage is substantial for cash-pay patients. Compounded empagliflozin preparations at Pennsylvania 503A pharmacies have been quoted in the $60, $120 per month range depending on dose and formulation, compared to the $680 brand list price. Some telehealth platforms serving Pennsylvania patients have integrated compounding pharmacy referral workflows for patients who document clinical need and cannot afford brand-name pricing.

The HealthRX clinical team uses a three-step cost-access framework for Pennsylvania patients prescribed empagliflozin:

1. First, confirm insurance tier and whether prior authorization applies. Submit the PA with complete documentation (diagnosis, labs, prior therapy) on the first attempt to avoid delays.
2. If commercially insured and ineligible for government programs, apply for the Boehringer Ingelheim/Lilly savings card immediately at the time of prescribing.
3. If uninsured or underinsured and the savings card is not available, request a referral to a licensed Pennsylvania 503A compounding pharmacy after confirming the pharmacy's current FDA-compliance status for empagliflozin sourcing.

Quality-control data on compounded SGLT2 inhibitors are limited. A 2021 analysis published in JAMA Internal Medicine examined compounded medications broadly and found potency variability of up to 25% in some preparations [11]. Patients choosing compounded empagliflozin should ask the pharmacy for a certificate of analysis (COA) confirming potency testing for each batch.

Telehealth Prescribing of Jardiance in Pennsylvania

Empagliflozin is a Schedule-unscheduled (non-controlled) prescription drug. Pennsylvania law permits telehealth prescribing of non-controlled medications following a valid prescriber-patient relationship established via synchronous audio-video visit [12]. The prescriber must be licensed in Pennsylvania or hold a qualifying interstate compact licensure.

A telephone-only (audio without video) encounter does not satisfy the Ryan Haight Act's or Pennsylvania's telehealth prescribing requirements for most clinical contexts, though Pennsylvania's temporary COVID-era waivers have largely expired. Patients should confirm their telehealth platform uses HIPAA-compliant video technology for the initial consultation.

HealthRX providers licensed in Pennsylvania conduct synchronous video visits for Jardiance prescribing. The initial visit reviews cardiovascular risk factors, kidney function (eGFR), current medications, and diabetes management history. Baseline labs, specifically eGFR and HbA1c, are required before prescribing; Pennsylvania patients can complete these at any LabCorp or Quest Diagnostics location with a provider-ordered requisition.

Empagliflozin is contraindicated when eGFR falls below 20 mL/min/1.73 m² for the T2D indication and below 20 for CKD [1]. The ADA 2023 Standards of Care recommend against initiating SGLT2 inhibitors at eGFR <20, but note that patients already on the drug may continue it down to lower thresholds for cardiorenal protection [7].

What Is the Cheapest Way to Get Jardiance in Pennsylvania?

The lowest-cost path depends on insurance status. Four scenarios cover most Pennsylvania patients:

Commercially insured with Tier 3 or 4 placement. Use the Boehringer Ingelheim/Lilly savings card. After the card, most patients pay $10, $40 per fill. This is the most common situation for employed Pennsylvania adults.

Pennsylvania Medicaid enrollees. Pursue prior authorization with full clinical documentation. Approved patients pay $0, $3.50. This path takes three to ten business days when documentation is complete.

Medicare Part D enrollees. The $2,000 annual out-of-pocket cap effective 2025 under the Inflation Reduction Act significantly limits total exposure [9]. Check your plan's formulary tier in October; switching to a plan that places Jardiance on a lower tier may save hundreds annually.

Uninsured or underinsured cash-pay patients. Boehringer Ingelheim's PAP provides free brand-name Jardiance for qualifying patients. For those who do not qualify for the PAP, a licensed Pennsylvania 503A compounding pharmacy may offer empagliflozin at $60, $120/month, subject to the regulatory caveats described above.

Generic empagliflozin is not yet available in the United States as of mid-2025. The Jardiance patent portfolio extends protection through at least 2025 for the primary compound, with secondary patents potentially extending market exclusivity further [13]. When generics do enter, Pennsylvania Medicaid and insurance formularies will likely shift coverage rapidly to the lower-cost alternative.

Empagliflozin Clinical Efficacy: Why Payers Cover It

Pennsylvania insurers and Medicaid MCOs do not cover expensive brand-name drugs without clinical justification. The evidence base for empagliflozin is among the strongest in its drug class.

The EMPA-REG OUTCOME trial (N=7,020, median follow-up 3.1 years) found a number needed to treat (NNT) of 39 to prevent one cardiovascular death over the study period [2]. That NNT compares favorably with many well-established cardiovascular interventions.

EMPA-KIDNEY (N=6,609) enrolled patients with eGFR 20, 44 or eGFR 45, 89 with albuminuria, nearly 45% of whom had no diabetes at baseline, demonstrating that the renal benefit extends beyond T2D [5]. The primary composite endpoint (kidney disease progression or cardiovascular death) occurred in 13.1% of the empagliflozin group vs. 16.9% of the placebo group (HR 0.72, P<0.001) [5].

The FDA Jardiance label approved indications as of 2024 include: T2D to improve glycemic control in adults, cardiovascular death reduction in adults with T2D and established CVD, heart failure (HFrEF and HFpEF) hospitalization reduction, and CKD progression risk reduction [1]. Payers use the label indications to set coverage criteria, so documentation should align with one of these four categories.

The 2022 AHA/ACC Guideline for HF management states: "In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce HF hospitalizations and cardiovascular mortality" (Class I, LOE A) [8]. Pennsylvania commercial insurers and Medicaid MCOs reference this guideline in their clinical coverage criteria documents.

Monitoring Requirements and Drug Interactions Relevant to Pennsylvania Prescribers

Empagliflozin requires baseline and periodic eGFR monitoring because efficacy diminishes at lower kidney function levels and the drug is contraindicated below eGFR 20 for its glycemic indication [1]. Blood pressure monitoring matters because SGLT2 inhibitors produce a modest osmotic diuresis that may lower systolic BP by 3 to 5 mmHg, which is beneficial in most patients but can cause orthostatic hypotension in those already on multiple antihypertensives [14].

Genital mycotic infections occur in roughly 6 to 8% of women and 3 to 4% of men using empagliflozin, based on EMPA-REG OUTCOME safety data [2]. Pennsylvania prescribers should counsel patients proactively. Euglycemic diabetic ketoacidosis (eDKA), though rare, requires holding empagliflozin 3 to 4 days before planned surgery or prolonged fasting [1].

Drug interactions of clinical note include: loop diuretics (additive volume depletion risk), insulin and sulfonylureas (hypoglycemia risk requiring dose reduction), and lithium (SGLT2-induced diuresis may raise lithium levels) [15]. The FDA label provides full interaction guidance [1].

Finding a Pennsylvania Provider Who Prescribes Empagliflozin

Primary care physicians, endocrinologists, cardiologists, and nephrologists all routinely prescribe empagliflozin in Pennsylvania. The drug's multi-indication label means a cardiologist managing HF and an endocrinologist managing T2D may both be prescribing it to the same patient, occasionally without coordination.

Pennsylvania's medical license lookup is available through the Pennsylvania Department of State Bureau of Professional and Occupational Affairs. Telehealth platforms including HealthRX that hold Pennsylvania provider licenses can initiate and manage empagliflozin therapy via video visit for clinically appropriate patients.

The initial telehealth visit for empagliflozin at HealthRX requires recent labs (eGFR and HbA1c within 90 days), a list of current medications, and a documented diagnosis that matches one of the FDA-approved indications. Patients with eGFR <20 mL/min/1.73 m² are not candidates for initiation; those with eGFR between 20 and 44 may still receive the drug for CKD or HF indications under current labeling [1].